Advances in JAK Inhibitors for Atopic Dermatitis: Insights from the 2025 AAD Conference

ATOPIC dermatitis (AD) is one of the most common chronic inflammatory skin diseases in the world, affecting 15-25% of children and 3-7% of adults. 1,2Beyond its physical burden, AD is associated with allergic, cardiovascular, and psychiatric comorbidities, further reducing patients' quality of life. 3,4Given its chronic and systemic nature, effective long-term management of AD is essential and makes newer therapies increasingly important. 5JAK inhibitors (JAKi) in particular have emerged as a novel medication class that modulate both Th1 and Th2 pathways, offering a promising treatment alternative for patients with moderate-to-severe AD.The recent 2025 American Academy of Dermatology (AAD) Annual Meeting featured several updates and reviews on JAKi by leading experts in the field, which the authors summarize in greater detail below.